Association between integrase strand transfer inhibitor (INSTIs) use with insulin resistance and incident diabetes mellitus in persons living with HIV: A systematic review and meta-analysis protocol.
Frank Mulindwa, Habiba Kamal, Barbara Castelnuovo, Robert C Bollinger, Jean-Marc Schwarz, Nele Brussealers
Author Information
Frank Mulindwa: Infectious Diseases Institute, Makerere University, Kampala, Uganda. ORCID
Habiba Kamal: Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Barbara Castelnuovo: Infectious Diseases Institute, Makerere University, Kampala, Uganda.
Robert C Bollinger: School of Medicine, Johns Hopkins University (JHU), Baltimore, MD, United States of America.
Jean-Marc Schwarz: School of Medicine, University of California San Francisco, San Francisco, CA, United States of America.
Nele Brussealers: Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
INTRODUCTION: Poeple living with HIV have higher prevalence of diabetes mellitus and metabolic perturbations compared to non-HIV populations. Diabetes and metabolic syndrome co-morbidities add significant burden to HIV care. Currently, WHO recommends integrase strand transfer inhibitors (INSTIs) as the first or second line therapy in people with HIV due to overall good tolerability and safety profile. However, whether INSTI use increases the risk of incident diabetes (with or without metabolic syndrome) compared to other anti-retroviral therapies (ART) is controversial. In this systematic review and meta-analysis, we aim to examine this risk in HIV-positive populations receiving INSTIs compared to other ART regimens (not containing INSTIs). METHODS AND ANALYSIS: The study will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement and the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines. This protocol adheres to the Standard Protocol Items for reporting systematic reviews and meta-analyses checklist. Eligibility criteria will be original peer-reviewed published articles and conference abstracts with no language or geographical restriction; that report the ocurrence of diabetes mellitus as a discrete outcome or part of metabolic syndrome, in adult PLWHIV receiving INSTIs compared to other ART regimens. PubMed/ Medline, Web of Science, Embase and Cochrane Database of Systematic Reviews will be searched from 1st- January-2000 to 31st-January-2022. Per our a priori, screening, inclusion and data extraction will be conducted separately by two investigators, and a senior researcher will be consulted in case of disagreement. The quality of included studies will be assessed by the Newcastle-Ottawa Scale (NOS) for cohort and case-control studies and the revised Cochrane risk-of-bias tool (ROB2) for randomized controlled trials. The quantitative synthesis of the study outcomes will be explored in different subgroups and sensitivity analyses. Meta regression will also be performed to further test the predictors of the outcome. ETHICS AND DISSEMINATION: Ethical approval is waived as the study is a review of published litterature. The analyses will be presented in conferences and published as a scientific article. TRIAL REGISTRARTION: PROSPERO registration number is; CRD42021273040.
References
Int J STD AIDS. 2017 May;28(6):626-628
[PMID: 27733708]
AIDS. 2017 Jun 19;31(10):1499-1500
[PMID: 28574967]
